UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

COMPLETE ANDROGEN BLOCKADE FOR PROSTATE CANCER: WHAT WENT WRONG?

The Journal of urology, 2000-07, Vol.164 (1), p.3-9

2000

Volltextzugriff (PDF)

A prospective study of suramin-induced peripheral neuropathy

Brain (London, England : 1878), 1996-12, Vol.119 (6), p.2039-2052

1996

Volltextzugriff (PDF)

Suramin, an Active Drug for Prostate Cancer: Interim Observations in a Phase I Trial

JNCI : Journal of the National Cancer Institute, 1993-04, Vol.85 (8), p.611-621

1993

Volltextzugriff (PDF)

Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy

Journal of clinical oncology, 1995-12, Vol.13 (12), p.2944-2953

1995

Volltextzugriff (PDF)

Preliminary evaluation of a short course of estramustine phosphate and docetaxel (Taxotere) in the treatment of hormone-refractory prostate cancer

Seminars in oncology, 1999-10, Vol.26 (5 Suppl 17), p.45

1999

Volltextzugriff (PDF)

Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer

Journal of clinical oncology, 1995-09, Vol.13 (9), p.2174-2186

1995

Volltextzugriff (PDF)

Development and validation of a pharmacokinetically based fixed dosing scheme for suramin

Journal of clinical oncology, 1995-09, Vol.13 (9), p.2187-2195

1995

Volltextzugriff (PDF)

A Phase I Clinical and Pharmacological Evaluation of Sodium Phenylbutyrate on an 120-h Infusion Schedule

Clinical cancer research, 2001-10, Vol.7 (10), p.3047-3055

2001

Volltextzugriff (PDF)

Acute abdomen in renal transplant recipients. Epidemiology and treatment in not referral transplantation centers

Il Giornale di chirurgia, 2010-11, Vol.31 (11-12), p.497-501

2010

Volltextzugriff (PDF)

Outcome of patients with metastatic chromophobe renal cell carcinoma treated with sunitinib

Annals of oncology, 2016-10, Vol.27, p.vi289-vi289

2016

Volltextzugriff (PDF)

Atrasentan, an Endothelin-Receptor Antagonist for Refractory Adenocarcinomas: Safety and Pharmacokinetics

Journal of clinical oncology, 2002-04, Vol.20 (8), p.2171-2180

2002

Volltextzugriff (PDF)

Clinical conduct and nursing quality of life in prostate cancer: Prostate cancer

Hematology/oncology clinics of North America, 2001-06, Vol.15 (3), p.573-581

2001

Volltextzugriff (PDF)

Ocular Symptoms and Signs Associated With Suramin Sodium Treatment for Metastatic Cancer of the Prostate

American journal of ophthalmology, 1996-03, Vol.121 (3), p.291-296

1996

Volltextzugriff (PDF)

Improvement of potato virus y (PVY) detection and quantitation using PVYN- and PVYO-specific real-time RT-PCR assays

Journal of virological methods, 2006-06, Vol.134 (1-2), p.261-266

2006

Volltextzugriff (PDF)

Rapid disease progression after the administration of bicalutamide in patients with metastatic prostate cancer

Urology (Ridgewood, N.J.), 1999-10, Vol.54 (4), p.745-745

1999

Volltextzugriff (PDF)

Suramin: development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer

Journal of clinical oncology, 1994-01, Vol.12 (1), p.166-175

1994

Volltextzugriff (PDF)

Correlation between serum PSA and testosterone (T) kinetics in patients (pts) with biochemically relapsed prostate cancer (BRPC) (M0), after local treatment (tx), treated with intermittent androgen deprivation (IAD)

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.4641-4641

2010

Volltextzugriff (PDF)

Docetaxel treatment in the elderly patient with hormone refractory prostate cancer

Clinical interventions in aging, 2007-01, Vol.2 (4), p.555-560

Sinibaldi, Victoria J

2007

Volltextzugriff (PDF)

PSA doubling time (PSADT) and serum testosterone (T) during intermittent androgen deprivation (IAD) in patients with biochemically relapsed prostate cancer (BRCP; M0): Potential predictive implications

Journal of clinical oncology, 2011-03, Vol.29 (7_suppl), p.150-150

2011

Volltextzugriff (PDF)

Comparison of sunitinib versus temsirolimus in patients with poor risk metastatic renal cell carcinoma

European urology supplements : official journal of the European Association of Urology, 2016-12, Vol.15 (13), p.e1740-e1740

2016

Volltextzugriff (PDF)

Outcome of octogenarian versus young patients with metastatic renal cell carcinoma, treated with sunitinib

European urology supplements : official journal of the European Association of Urology, 2016-12, Vol.15 (13), p.e1741-e1741

2016

Volltextzugriff (PDF)

Evaluation of biomarkers of survival response in hormone-refractory prostate cancer patients treated with suramin

Cancer epidemiology, biomarkers & prevention, 1998-07, Vol.7 (7), p.631-634

1998

Volltextzugriff (PDF)

Prostate cancer treatment strategies based on tumor-specific biological principles : Future directions

Seminars in oncology, 1996-12, Vol.23 (6), p.56-62

1996

Volltextzugriff (PDF)

PSA doubling time (PSADT) and serum testosterone (T) during intermittent androgen deprivation (IAD) in patients with biochemically relapsed prostate cancer (BRCP; M0): Potential predictive implications

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.e15006-e15006

2011

Volltextzugriff (PDF)

Safety and efficacy of ketoconazole (K) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Contemporary experience and prognostic indicators

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.e15007-e15007

2011

Volltextzugriff (PDF)

1 – 25 von 142

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(110)
Mit Volltextzugriff
(111)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(71)
Humans
(56)
Life Sciences & Biomedicine
(55)
Male
(42)
Biological And Medical Sciences
(40)
Medical Sciences
(28)
Middle Aged
(28)
Female
(25)
Oncology
(24)
Aged
(22)
Pharmacology. Drug Treatments
(22)
Adult
(19)
Antineoplastic Agents
(18)
Chemotherapy
(17)
Prostatic Neoplasms - Drug Therapy
(15)
Fundamental And Applied Biological Sciences. Psychology
(14)
Physical Sciences
(14)
Animals
(11)
Urology
(11)
Chemistry
(10)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

COMPLETE ANDROGEN BLOCKADE FOR PROSTATE CANCER: WHAT WENT WRONG?

A prospective study of suramin-induced peripheral neuropathy

Suramin, an Active Drug for Prostate Cancer: Interim Observations in a Phase I Trial

Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy

Preliminary evaluation of a short course of estramustine phosphate and docetaxel (Taxotere) in the treatment of hormone-refractory prostate cancer

Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer

Development and validation of a pharmacokinetically based fixed dosing scheme for suramin

A Phase I Clinical and Pharmacological Evaluation of Sodium Phenylbutyrate on an 120-h Infusion Schedule

Acute abdomen in renal transplant recipients. Epidemiology and treatment in not referral transplantation centers

Outcome of patients with metastatic chromophobe renal cell carcinoma treated with sunitinib

Atrasentan, an Endothelin-Receptor Antagonist for Refractory Adenocarcinomas: Safety and Pharmacokinetics

Clinical conduct and nursing quality of life in prostate cancer: Prostate cancer

Ocular Symptoms and Signs Associated With Suramin Sodium Treatment for Metastatic Cancer of the Prostate

Improvement of potato virus y (PVY) detection and quantitation using PVYN- and PVYO-specific real-time RT-PCR assays

Rapid disease progression after the administration of bicalutamide in patients with metastatic prostate cancer

Suramin: development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer

Correlation between serum PSA and testosterone (T) kinetics in patients (pts) with biochemically relapsed prostate cancer (BRPC) (M0), after local treatment (tx), treated with intermittent androgen deprivation (IAD)

Docetaxel treatment in the elderly patient with hormone refractory prostate cancer

PSA doubling time (PSADT) and serum testosterone (T) during intermittent androgen deprivation (IAD) in patients with biochemically relapsed prostate cancer (BRCP; M0): Potential predictive implications

Comparison of sunitinib versus temsirolimus in patients with poor risk metastatic renal cell carcinoma

Outcome of octogenarian versus young patients with metastatic renal cell carcinoma, treated with sunitinib

Evaluation of biomarkers of survival response in hormone-refractory prostate cancer patients treated with suramin

Prostate cancer treatment strategies based on tumor-specific biological principles : Future directions

PSA doubling time (PSADT) and serum testosterone (T) during intermittent androgen deprivation (IAD) in patients with biochemically relapsed prostate cancer (BRCP; M0): Potential predictive implications

Safety and efficacy of ketoconazole (K) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Contemporary experience and prognostic indicators

Suchergebnisse filtern